Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neoprobe Reports 2008 Results
For the fourth quarter of 2008, Neoprobe had a net loss of $1.2 million or $0.02 per share compared to a net loss of $1.9 million or $0.03
For the fourth quarter of 2008, Neoprobe had a net loss of $1.2 million or $0.02 per share compared to a net loss of $1.9 million or $0.03
Prior to joining Biolase, Mr Capallo spent 10 years as director of corporate accounting for Irvine-based Interpore International, a manufacturer and distributor of orthopedic products including spinal implants,
Mr Buckley joins Neugenesis from Genitope, where he was former vice president of manufacturing. Prior to that, he was vice president-Bexxar operations for the Corixa. Dorsey Stuart, chairman
Mr Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. The addition of Mr Prondzynski expands Hospira’s board to 10
Mr Przybyl is replacing Tom Anderson, Ani’s founding CEO, who is leaving to pursue other opportunities. Mr Anderson will remain on Ani’s board of directors. Most recently, Mr
According to the company, the medical device expands its portfolio, because the DVS-HFT dosimeter is specifically calibrated for use with radiation therapy protocols that give patients higher single
In his new position, Dr Nielsen, a founder of Merrimack who has been with the company since inception, continues to be responsible for the strategic direction of the
A total of $3 million of additional milestone payments from Ovation are pending as a result of the approval of ATryn by the FDA. In addition to the
The abbreviated new drug application approval is the result of an extensive, multi-year development program. Efforts to commercialize the product are now being pursued by Synerx. Ovide lotion
Highlights Pre-tax profits increased 128.3% to GBP6.8m (H1 2008: GBP3 million before potential offer related costs of GBP0.25 million). Product range expanded by 17.3% to 47,870 (31 December